A “Yellow Submarine” in Dermoscopy

Francesca Satolli1, Miriam Rovesti1, Alfredo Zucchi1, Marco Gandolfi1, Claudio Feliciani1, Georgi Tchernev2,3, Uwe Wollina4, Serena Gianfaldoni5, Torello Lotti6

1Dermatology, Via Gramsci 14, Parma, Parma 43126, Italy; 2”Onkoderma”: Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; 3Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, General Skobelev 26, 1606 Sofia, Bulgaria; 4Department of Dermatology and Allergology, Teaching Hospital Dresden-Friedrichstadt, Academic Friedrichstrasse 41, 01067 Dresden, Germany; 5University G. Marconi of Rome - Dermatology and Venereology, University G. Marconi of Rome Rome, Rome 00192, Italy; 6University of Rome G. Marconi, Rome 00186, Institute of Dermatology, Italy

Abstract

BACKGROUND: Histiocytic sarcoma (HS) is an extremely rare, non-Langerhans cell tumor. HS affects especially adults, its etiology is unknown yet. Skin can be interested by papules or nodules, single or multiple.

CASE REPORT: A Caucasian man in his late 40s came to our clinic for a naevi evaluation. During the visit, a rose papulonodular lesion was observed in the lumbar region. This lesion was completely asymptomatic, and it had been there for an indefinite period. The clinical evaluation revealed that the lesion appeared elevated, of 9 x 15 mm in dimension, symmetrical and of a homogeneous pinkish colour. The videodermoscopical evaluation revealed a homogeneous yellow central pattern, polymorphic vessels, an eccentric peripheral pigmentation and a white collar. An excisional biopsy was performed. The morphology and the expression of CD163, CD68 and/or lysozyme to the immunophenotypic analysis, revealed the true nature of the lesion.

CONCLUSION: HS is usually diagnosed at an already advanced clinical stage and it has a high mortality rate even today. Dermoscopy, showing a yellow and distributed homogeneously colour, can facilitate its hard diagnosis.

Introduction

Histiocytic sarcoma (HS) is an extremely rare, non-Langerhans cell disorder with morphologic and immunophenotypic evidence of histiocytic disorders [1]. HS affects all ages, but it is more common in adults (46–55 years). The aetiology of this disorder is unknown [2]. Systemic symptoms (such as fever, night sweats, and weakness) and other skin, hepatosplenic or intestinal manifestations could appear. For some years there has been confusion about this type of a tumour and its terminology. Nonetheless, thanks to the advances in knowledge in the field of genetics and biology in recent years, we are today able to classify and recognize these kinds of hematologic neoplasms.

The latest WHO classification of lymphomas, published in 2008 [3] and updated in 2016 [4], describes the HS within the histiocytic and dendritic cells neoplasms; this group includes pathologies which share the same functional properties of their normal counterpart (phagocytosis and/or processing and presentation of antigens) rather than their cell of origin [4].

Case Report

A Caucasian man in his late 40s came to our clinic for a naevi evaluation.

During the visit, a rose papulonodular lesion was observed in the lumbar region (Figure 1: A, B). This lesion was completely asymptomatic, and it had been there for an indefinite period. The clinical evaluation showed that the lesion appeared elevated, of 9×15 mm in dimension, symmetrical and a homogeneous pinkish colour.
Suspecting a malignant lesion, also a videodermoscopy of the lesion was also immediately performed, and this revealed a homogeneous yellow central pattern, polymorphic (arborizin, dotted and glomerular) vessels, an eccentric peripheral pigmentation and a white collar (Figure 2). The patient has always been in good health and was not taking any drugs. He had a skin type II according to Fitzpatrick’s classification; he did not suffer from any skin diseases and did not have melanoma familiarity. In the previous check-ups of neavi no atypical lesions had been observed.

Discussion

Even though the lymph nodes are the most common site of HS presentation, the gastrointestinal tract, the soft tissue and the skin could also be affected. Skin manifestations can be isolated or associated with systemic involvement. A cutaneous HS could appear as single or multiple papules and nodules of a light colour. The clinical differential diagnosis must take into account other cutaneous lesions: amelanotic melanoma, B or T cell lymphoma, dermatofibroma, dermatofibrosarcoma protuberans, juvenile xanthogranuloma, etc.

With dermoscopy, the cutaneous HS is predominantly yellow, distributed homogeneously. This colour, in dermoscopy, was investigated by Cavacchini et al. some years ago [5]. In the case of

An excisional biopsy was performed. The morphology showed a diffuse proliferation of large cells, with grooved and indented nuclei and abundant eosinophilic cytoplasm (Figure 3: A, B). The immunohistochemistry of the surgical specimens showed cells with positivity for CD68, CD163 and CD4, with negativity for S100, CD34 and HMB45 (Figure 4). The Ki67 index was about 18% (Figure 4).
HS, the yellow may appear in various shades and is the background to some polymorphic vessels (arborising, dotted or glomerular) and a white-pinkish collar. In fact, the presence of polymorphic vessels represents a highly risky dermoscopic pattern that can be seen not only in amelanotic melanoma or Spitz naevi [6] but also in other malignant lesions, such as an HS. When confronted with this kind of lesion, excisional biopsy is the most accurate diagnostic method. The morphology is characterized by large atypical pleomorphic cells with eosinophilic cytoplasm and large, round to oval, irregular nuclei [1].

The immunophenotype is characterized by the expression of one or more histiocytic markers, such as CD163, CD68 and lysozyme [1]. CD163, a haemoglobin scavenger receptor whose expression is limited to neoplasms of macrophage/histiocytic lineage, is more specific than CD68, and a strong immunoreactivity for this antigen is suggestive of histiocytic differentiation [2]. The Ki-67 index is variable. Staging studies, including imaging studies such as computed tomography (CT) or a combined positron emission tomography (PET/CT), should be performed after the diagnosis to determine the extent of the disease.

Unfortunately, HS is usually diagnosed at an already advanced clinical stage, and it does not have a good response to chemotherapy. This tumour has a high mortality rate and, in fact, most patients die from the progressive disease within two years [7].

Due to the aggressive course and the limited treatment options of this tumour, performing a careful clinical and dermoscopic evaluation is essential to help the final histological diagnosis. Over the last ten years, there has been various case reports in the literature regarding patients with cutaneous or subcutaneous histiocytic sarcoma. Only one of them [8] focused on the use of dermoscopy on this kind of lesion.

Dermoscopy, a non-invasive analysis technique, used especially for the early detection of melanoma, an instrument that is becoming increasingly widespread and more commonly used in dermatology clinics; it represents a tool which helps increase the low clinical sensitivity of the naked eye [9].

In conclusion, the early diagnosis of a rare and malignant tumour-like HS currently remains hard. However, dermoscopy can facilitate it and lead to quickly performing an excisional biopsy, thus improving the prognosis for patients.

When dermoscopy notices the colours pink or black in a lesion, it should indicate to dermatologists that something may be wrong. Nevertheless, yellow too could be suspicious, and it is a wake-up call in dermoscopy… beware of the “yellow submarine”!

References
1. Takahashi E, Nakamura S. Histiocytic Sarcoma: An Updated Literature Review Based on 2008 WHO classification. J Clin Exp Hematop. 2013; 53(1). https://doi.org/10.3960/j.irst.53.1
2. Ansari J, Nagash AR, Munker R, et al. Histiocytic sarcoma as a secondary malignancy: photobiology, diagnosis, and treatment. Eur J Haematol. 2016; 97(1): 9–16. https://doi.org/10.1111/ejh.12752 PMid:26990812
3. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. IARC. 2008; 4:270–319.
4. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127:2375–2390. https://doi.org/10.1182/blood-2016-01-643569 PMid:26980727 PMCid:PMC4874220
5. Cavicchini S, Tourlaki A, Bottini, et al. Dermoscopy of Solitary Yellow Lesions in Adults. Arch Dermatol. 2008; 144(10):1412. https://doi.org/10.1001/archderm.144.10.1412 PMid:18936419
6. Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumours: a dermoscopy study. Arch Dermatol. 2004; 140(12):1485–9. https://doi.org/10.1001/archderm.140.12.1485 PMid:15611426
7. Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epitheloid malignancy. Am J Surg Pathol. 2004; 28:1133–1144, https://doi.org/10.1097/01.pas.0000131541.95394.23 PMid:15316312
8. Escandell I, Ramon MD, Sanchez S, et al. Dermoscopic characteristics of a cutaneous histiocytic sarcoma in a young patient. J Am Acad Dermatol. 2017; 76(2S1): S5–S7.
9. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus --based interdisciplinary guideline-- Update 2016. Eur J Cancer. 2016; 63: 201–17. https://doi.org/10.1016/j.ejca.2016.05.005 PMid:27367293